Details for Patent: 10,376,517
✉ Email this page to a colleague
Which drugs does patent 10,376,517 protect, and when does it expire?
Patent 10,376,517 protects REZDIFFRA and is included in one NDA.
This patent has sixty-nine patent family members in twenty-one countries.
Summary for Patent: 10,376,517
| Title: | Methods of synthesizing thyroid hormone analogs and polymorphs thereof |
| Abstract: | The disclosure describes methods of synthesis of pyridazinone compounds as thyroid hormone analogs and their prodrugs. Preferred methods according to the disclosure allow for large-scale preparation of pyridazinone compounds having high purity. In some embodiments, preferred methods according to the disclosure also allow for the preparation of pyridazinone compounds in better yield than previously used methods for preparing such compounds. Also disclosed are morphic forms of a pyridazinone compound. Further disclosed is a method for treating resistance to thyroid hormone in a subject having at least one TRĪ² mutation. |
| Inventor(s): | Taub Rebecca, Reynolds Charles H., Shu Lianhe, Wang Ping, Choi Duk Soon |
| Assignee: | |
| Application Number: | US15949389 |
|
Patent Claim Types: see list of patent claims |
Drugs Protected by US Patent 10,376,517
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Madrigal | REZDIFFRA | resmetirom | TABLET;ORAL | 217785-001 | Mar 14, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF ADULTS WITH NONCIRRHOTIC NONALCOHOLIC STEATOHEPATITIS (NASH) WITH MODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3 FIBROSIS) | ⤷ Sign Up | ||||
| Madrigal | REZDIFFRA | resmetirom | TABLET;ORAL | 217785-002 | Mar 14, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF ADULTS WITH NONCIRRHOTIC NONALCOHOLIC STEATOHEPATITIS (NASH) WITH MODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3 FIBROSIS) | ⤷ Sign Up | ||||
| Madrigal | REZDIFFRA | resmetirom | TABLET;ORAL | 217785-003 | Mar 14, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF ADULTS WITH NONCIRRHOTIC NONALCOHOLIC STEATOHEPATITIS (NASH) WITH MODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3 FIBROSIS) | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,376,517
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 092872 | ⤷ Sign Up | |||
| Australia | 2013315017 | ⤷ Sign Up | |||
| Brazil | 112015005891 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
